



MAIL STOP PCT
Attorney Docket No. 26887U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ZIMMERMANN et al.

Serial No. 10/545,190

Filed: August 11, 2005

International Application. No.: PCT/EP04/50135

International Filing Date: 16 February 2004 (16.02.2004)

For: **6-SUBSTITUTED IMIDAZOPYRAZINES**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- [XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
[] Certification report(e) below; and
[] a check in the amount as required by 1.17(p).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or

[] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

Date filed: November 9, 2005

NATH & ASSOCIATES PLLC
1030 15th St., N.W., 6th Fl.,
Washington, D.C. 20005-1503
(202) 775-8383

GMN/SMM/sw (IDS.Statement)

By: 

Gary M. Nath
Reg. No. 26,965
Sheldon M. McGee
Reg. No. 50,454
Customer No. 34375



FORM PTO-1449

INFORMATION DISCLOSURE CIRCULAR

Attorney Docket
26887USerial
No.10/545,190Applicant
ZIMMERMANN et al.Filed
August 11, 2005Group Art Unit
Unknown

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue/Pub Date	Name	Class	Sub-Class	Filing Date
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	AC	0 204 285 A1	10 Dec. 1986	EP			N/A
	AD	89/00570 A1	26 Jan. 1989	WO			Abstract
	AE	07242666	19 Sep. 1995	JP			Abstract
	AF	02/060492 A1	8 Aug. 2002	WO			N/A
	AG	99/28322 A1	10 Jun. 1999	WO			N/A
	AH	2004/026310 A1	1 Apr. 2004	WO			N/A

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AI	XP-002008621: Kaminski, J.J., et al., "Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazo[1,2-a]pyridines and Analogues", <u>J. Med. Chem.</u> , Vol. 30, No.11, pages 2031-2046, (1987).
	AJ	XP-002190259: Wermuth, C.G., "Molecular Variations Based on Isosteric Replacements", <u>THE PRACTICE OF MEDICINAL CHEMISTRY</u> , Ch.13, pages 203-237, (1996).
	AK	

Examiner

/Jeffrey Murray/

Date Considered 04/09/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./